Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PFSABullishM&Anews

High materiality7/10

PFSA climbs on ISO 13485 clearance and EU MDR progress for Lumee

Sep 24, 2026, 2:25 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory progress toward CE marking and potential acquisition synergies can unlock EU revenue and expand PFSA's diagnostics footprint; however, timing is uncertain and downside risk remains until milestones are de-risked, as seen in prior MDR timelines.

AI summary

What happened, with direct paths to the underlying reporting

Profusa jumped after GMED affirmed ISO 13485 QMS certification, advancing Lumee Oxygen's MDR and EU CE marking path. The company also disclosed an option to acquire G3 Vision Labs, potentially creating a CLIA-certified diagnostics platform with estimated 2025 sales of about $111 million if exercised. Timelines for CE marking remain uncertain.

PFSA surges after GMED cert for ISO 13485 QMS; EU MDR CE mark progress.
Lumee Oxygen Platform enables real-time tissue oxygen monitoring; MDR path advancing.
G3 Vision Labs option to acquire; 2025 sales ~ $111 million if exercised.
PFSA up 50.70% to $3.08; near 52-week low of $1.58.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

PFSA climbs on ISO 13485 clearance and EU MDR progress for Lumee

Profusa Stock Spikes As Lumee System Targets Research Market

Profusa Stock Soars—To 12 Cents—On Debt Restructuring